Cryoport's IntegriCell® Services Chosen by Verismo for Advanced Cell Therapies
Cryoport's IntegriCell® Services Chosen by Verismo for Advanced Cell Therapies
Cryoport, Inc., a leading provider of temperature-controlled supply chain solutions for the life sciences, has announced an exciting partnership with Verismo Therapeutics, a clinical-stage company focused on CAR T cell therapies. This collaboration centers around Cryoport's IntegriCell® cryopreservation services, which will play a crucial role in supporting Verismo's innovative multi-chain KIR-CAR platforms, specifically for their lead candidates, SynKIR™-110 and SynKIR™-310.
Significance of the Collaboration
Verismo is pioneering advancements in the treatment of solid tumors and B cell-associated disorders through its KIR-CAR technology. As they progress into human clinical trials, the need for robust cryopreservation solutions has become increasingly evident. IntegriCell® ensures that Verismo can maintain the quality and functionality of its leukapheresis starting materials while adhering to globally recognized good manufacturing practices (GMP).
Dr. Mark Sawicki, the CEO of Cryoport Systems, emphasized the importance of having a partner capable of refining and scaling critical processes in cellular therapy programs. The partnership allows Verismo to maintain its proprietary cryopreservation methodologies while benefitting from Cryoport's advanced bioprocessing and distribution infrastructures.
Bryan Kim, Verismo's CEO and Co-Founder, commented on the importance of a seamless integration of capabilities. IntegriCell's precision and commitment to process improvement are vital as Verismo continues to advance towards clinical and regulatory milestones, positioning them favorably in the competitive field of cell therapy.
IntegriCell’s Role in the Clinical Trials
The implementation of IntegriCell's services is structured to facilitate the cryopreservation needs for both of Verismo's lead programs.
- - SynKIR™-110 is being tested in the STAR-101 Phase 1 trial, focused on patients with advanced mesothelin-expressing solid tumors.
- - SynKIR™-310 is under evaluation in the CELESTIAL-301 Phase 1 trial for patients suffering from relapsed or refractory B-cell non-Hodgkin lymphomas.
Cryopreservation is a critical piece of the manufacturing puzzle, ensuring that high-quality starting materials are consistently available. The expertise offered by Cryoport in handling these demands helps Verismo mitigate risks and enhance the reliability of their supply chains.
Global Support and Future Directions
IntegriCell’s strategic centers located in Houston, Texas, and Liège, Belgium, ensure geographical coverage to support clinical and commercial development across both North America and Europe. This global reach identifies Cryoport not merely as a service provider but as an integral supply chain partner committed to the advancement of innovative therapies.
As the landscape of cell and gene therapies rapidly evolves, the need for reliable supply chain partners has never been more essential. Cryoport's IntegriCell was designed specifically to address this demand, offering a partnership that blends scientific credentials with necessary infrastructure.
In summary, the collaboration between Cryoport and Verismo Therapeutics is set to significantly impact the development of cutting-edge CAR T cell therapies. As they embark on this journey, their partnership not only enhances operational efficiencies but also propels them towards achieving significant therapeutic advancements over the coming years. With such innovative approaches to treating complex diseases, the future of medicine looks promising, backed by solid scientific partnerships that prioritize reliability and growth.
For further details on the groundbreaking work by Verismo Therapeutics, visit their official page Verismo Therapeutics.
About the Companies
Verismo Therapeutics is a groundbreaking force in the KIR-CAR technology space, with trials for SynKIR™-110 (NCT05568680) and SynKIR™-310 (NCT06544265) currently underway. The company focuses on addressing significant unmet medical needs in oncology.
Cryoport, Inc., traded on NASDAQ under CYRX, specializes in temperature-controlled logistics for the life sciences and is dedicated to minimizing risks and maximizing reliability in the supply chain. For more information on Cryoport, visit Cryoport, Inc..
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.